Does bacterial vaginosis recur, and what are the reasons for recurrence?

Does Bacterial Vaginosis Recur?

Yes, bacterial vaginosis (BV) recurs frequently—recurrence is not unusual and affects the majority of treated women, with rates exceeding 50-60% within 3-12 months after standard antibiotic therapy. 1, 2, 3

Why BV Recurs: Key Mechanisms

Sexual Transmission and Reinfection

• Having the same sexual partner before and after treatment nearly doubles the risk of recurrence (adjusted HR 1.9), as BV-associated bacteria are sexually exchanged between partners 4, 5, 6
• Women with a regular sex partner throughout follow-up have significantly higher recurrence rates 5
• Groundbreaking 2025 evidence demonstrates that treating male partners with combined oral metronidazole (400 mg twice daily) and topical 2% clindamycin cream for 7 days reduces female recurrence from 63% to 35% within 12 weeks (absolute risk reduction of 2.6 recurrences per person-year) 6
• Female sex partners are also associated with increased recurrence risk 5

Biofilm Persistence

• BV-associated bacteria form multi-species biofilms on vaginal epithelial cells that reduce antimicrobial penetration, allowing bacteria to persist after treatment and re-emerge 2, 3
• The biofilm structure itself contributes to both refractory disease and recurrence independent of antimicrobial resistance 2

Antimicrobial Resistance

• Drug-resistant pathogenic vaginal microbiota develop within the biofilm and vaginal canal, limiting treatment effectiveness 2
• Recurrence rates often exceed 60% despite standard therapy, highlighting resistance issues 2

Failure to Restore Protective Lactobacilli

• Women who achieve cure have different Lactobacillus species composition than those with recurrence—specifically higher levels of L. crispatus, L. gasseri, and L. jensenii 7
• L. iners dominance (rather than protective species like L. crispatus) persists in many women and fails to prevent recurrence 7, 3
• Failure to recolonize a favorable vaginal microbiome after antimicrobial treatment contributes to recurrence 3

Behavioral and Clinical Risk Factors

• Past history of BV significantly predicts recurrence 7, 5
• Inconsistent condom use increases recurrence risk (adjusted HR 1.9) 4
• Use of intravaginal devices (likely IUDs) increases recurrence 7
• Hormonal contraceptives containing estrogen reduce recurrence by half (adjusted HR 0.5), providing protective effect 4, 5
• Higher Nugent scores at day 7 post-treatment predict recurrence 7

Clinical Implications

Current Treatment Limitations

• Standard CDC-recommended regimens (metronidazole 500 mg orally twice daily for 7 days, or intravaginal alternatives) achieve initial cure rates of 78-84% but fail to prevent recurrence in most women 1
• No long-term maintenance regimen with any therapeutic agent is currently recommended by CDC guidelines 1
• Treatment of female partners alone is insufficient to achieve sustained cure 3

Emerging Strategies

• Partner treatment should now be strongly considered based on 2025 trial evidence showing significant benefit 6
• Combination antimicrobial regimens and probiotics are being investigated for refractory/recurrent disease 2
• Monitoring vaginal microbiota composition (particularly Lactobacillus species, Enterococcus, Ureaplasma, and Aerococcus) at day 7 post-treatment may predict recurrence risk 7

Common Pitfalls

• Treating the woman alone while ignoring her untreated sexual partner leads to reinfection 6
• Assuming recurrence represents treatment failure rather than reinfection or biofilm persistence 8, 3
• Not counseling about condom use and hormonal contraceptive benefits 4
• Failing to recognize that routine partner treatment was previously not recommended by CDC guidelines 1, but new evidence now supports this approach 6